20 Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res, 1991, 23: 12-20
[2]
21 Leite E B, Mota M C, de Abreu J R, et al. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol, 1990, 14: 81-88
[3]
22 Benarroch I S, de Salama Benarroch A R, Nano H, et al. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1977, 174: 47-51
[4]
23 Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor decreased by doxium (calcuim dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophthalmic Res, 1984, 16: 150-162
[5]
24 Benarroch I S, Brodsky M, Rubinstein A, et al. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res, 1985, 17: 131-138
[6]
25 Ribeiro M L, Seres A I, Carneiro A M, et al. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol, 2006, 244: 1591-1600
[7]
26 Javadzadeh A, Ghorbanihaghjo A, Adl F H, et al. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis, 2013, 19: 62-68
[8]
27 Sander B, Thornit D N, Colmorn L, et al. Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci, 2007, 48: 3983-3987
[9]
28 Benarroch I S, de Salama Benarroch A R, Nano H, et al. Calcium dobesilate as a treatment for capillary fragility in diabetic retinopathy. Ophthalmologica, 1974, 168: 370-375
[10]
29 Zhang X, Bao S, Lai D, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes, 2008, 57: 1026-1033
[11]
30 Leske M C, Wu S Y, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology, 2005, 112: 799-805
[12]
31 Varma R, Macias G L, Torres M, et al. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology, 2007, 114: 1332-1340
[13]
32 Benarous R, Sasongko M B, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci, 1167, 52: 7464-7469
[14]
33 Agroiya P, Philip R, Saran S, et al. Association of serum lipids with diabetic retinopathy in type 2 diabetes. Indian J Endocrinol Metab, 2013, 17: S335-S337
[15]
34 Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost, 2000, 26: 529-537
[16]
35 Schulz K F, Grimes D A. Generation of allocation sequences in randomised trials: chance, not choice. Lancet, 2002, 359: 515-519
[17]
36 Glasziou P, Chalmers I, Rawlins M, et al. When are randomised trials unnecessary? Picking signal from noise. Brit Med J, 2007, 334: 349-351
[18]
37 Guyatt G H, Oxman A D, Kunz R, et al. What is “quality of evidence” and why is it important to clinicians? Brit Med J, 2008, 336: 995-998
[19]
18 Jadad A R, Moore R A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17: 1-12
[20]
19 Larsen H W, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia, 1977, 13: 105-109
[21]
1 Centers for Disease Control and Prevention (CDC). Blindness caused by diabetes—Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep, 1996, 45: 937-941
[22]
2 Yau J W, Rogers S L, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35: 556-564
[23]
3 Xie X, Xu L, Yang H, et al. Frequency of diabetic retinopathy in the adult population in China: the Beijing Eye Study 2001. Int Ophthalmol, 2009, 29: 485-493
[24]
4 Xu J, Wei W B, Yuan M X, et al. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. Retina, 2012, 32: 322-329
[25]
5 Wang F H, Liang Y B, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology, 2009, 116: 461-467
[26]
6 ACCORD Study Group, ACCORD Eye Study Group, Chew E Y, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. New Engl J Med, 2010, 363: 233-244
[27]
7 Vekasi J, Koltai K, Gaal V, et al. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc, 2008, 39: 385-389
[28]
8 Aiello L P, Vignati L, Sheetz M J, et al. Oral protein kinase C b inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1392 eyes) with diabetic retinopathy in the Protein Kinase C b Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C b Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31: 2084-2094
[29]
9 Wilkinson-Berka J L, Rana I, Armani R, et al. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci, 2013, 124: 597-615
[30]
10 Tillin T, Orchard T, Malm A, et al. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study. J Hypertens, 2011, 29: 1457-1462
[31]
11 Ribeiro M L, Caillon P, Gamba G, et al. Efficacy of calcium dobesilate (Doxium？) on the blood-retinal barrier permeability in early diabetic retinopathy: a double-blind study. Invest Ophthalmol Vis Sci, 2004, 45: 4153-B614
[32]
12 Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology, 1258, 25: 66-71
[33]
13 Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Brit J Pharmacol, 1997, 121: 711-716
[34]
14 Graber R, Farine J C, Losa G A. Calcium dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis, 1998, 3: 41-49
[35]
15 Szabo M E, Haines D, Garay E, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol, 2001, 428: 277-286
[36]
16 Opreanu M, Lydic T A, Reid G E, et al. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest Ophthalmol Vis Sci, 1167, 51: 3253-3263
[37]
17 Leal E C, Martins J, Voabil P, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes, 2010, 59: 2637-2645
[38]
38 Charles P, Giraudeau B, Dechartres A, et al. Reporting of sample size calculation in randomised controlled trials: review. Brit Med J, 2009, 338: b1732
